The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Frederick Lansigan, Ian Barak, Brandelyn Pitcher, Sin-Ho Jung, Bruce D Cheson, Myron Czuczman, Peter Martin, Eric Hsi, Heiko Schöder, Scott Smith, Nancy L Bartlett, John P Leonard, Kristie A Blum, Frederick Lansigan, Ian Barak, Brandelyn Pitcher, Sin-Ho Jung, Bruce D Cheson, Myron Czuczman, Peter Martin, Eric Hsi, Heiko Schöder, Scott Smith, Nancy L Bartlett, John P Leonard, Kristie A Blum

Abstract

Follicular lymphoma (FL) patients treated with firstline R-CHOP who experience progression of disease (POD) within 2 years have a shorter survival than those who do not have POD within 2 years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown. We performed a retrospective analysis of 174 patients pooled from three frontline rituximab (R)-based nonchemotherapy doublet trials: R-galiximab (Anti-CD80, CALGB 50402), R-epratuzumab (Anti-CD22, CALGB 50701), and R-lenalidomide (CALGB 50803) to determine outcomes of early progressors and risk factors for early POD, defined as progression within 24 months from study entry. Twenty-eight percent (48/174) of patients had early POD. After adjusting for the Follicular Lymphoma International Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS compared with patients who did not progress within 2 years (HR = 4.33 (95% CI 1.50-12.5), P = 0.007). For early POD, the 2-year survival was 80% vs 99% for nonearly POD, and the 5-year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality.

Trial registration: ClinicalTrials.gov NCT00117975 NCT00553501 NCT01145495.

Keywords: PFS24; biologic agents; early progression; follicular lymphoma; immunotherapy.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Overall survival (separate TIFF file)

References

    1. Solal‐Celigny P. Follicular lymphoma international prognostic index. Curr. Treat. Options Oncol.. 2006;7(4):270‐275.
    1. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555‐4562.
    1. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first‐line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population‐based registry. Lancet Oncol. 2015;16(9):1111‐1122.
    1. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516‐2522.
    1. Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first‐line immunochemotherapy. Blood. 2016;128(8):1112‐1120.
    1. Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096‐1101.
    1. Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re‐treatment trial for low‐tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096‐3102.
    1. Martinelli G, Schmitz SF, Utiger U, et al. Long‐term follow‐up of patients with follicular lymphoma receiving single‐agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480‐4484.
    1. Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch‐and‐wait approach in patients with advanced‐stage, asymptomatic, non‐bulky follicular lymphoma: an open‐label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424‐435.
    1. Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti‐CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2012;23(9):2356‐2362.
    1. Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013;119(21):3797‐3804.
    1. Martin P, Jung S‐H, Johnson JL, et al. CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol 2014:32:5s, (suppl; abstr 8521). 2014.
    1. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457‐481.
    1. Sohani AR, Pitcher B, Chadburn A, et al. Interfollicular CD10 expression and follicular PD1 Tumor‐infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab‐based biologic therapy: an alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401). Blood. 2015;126:334‐334.
    1. Nabhan C, Zhou X, Day B‐M, et al. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am. J. Hematol.. 2016;91(8):770‐775.
    1. Kumagai S, Tashima M, Fujikawa J, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression‐free survival in follicular lymphoma. Int. J. Hematol.. 2014;99(6):737‐742.
    1. Marcheselli L, Bari A, Anastasia A, et al. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced‐stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Br. J. Haematol.. 2015;169(4):544‐551.
    1. Fouad‐Younes S, Beck A, Lossos IS, Levy R, Warnke RA, Natkunam Y. Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components. Am J Surg Pathol. 2010;34(9):1266‐1276.
    1. Xerri L, Huet S, Venstrom JM, et al. Rituximab treatment circumvents the prognostic impact of tumor‐infiltrating T‐cells in follicular lymphoma patients. Hum Pathol. 2017;64:128‐136.
    1. Le Gouill S, De Guibert S, Planche L, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96(8):1128‐1135.
    1. Sarkozy C, Huet S, Carlton VE, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG‐VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;8(5):8765‐8774.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere